Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.4900
+0.01673.53%
Post-market: 0.49850.0085+1.73%19:57 EDT
Volume:4.20M
Turnover:2.02M
Market Cap:64.19M
PE:-1.44
High:0.5033
Open:0.4890
Low:0.4500
Close:0.4733
52wk High:1.32
52wk Low:0.4414
Shares:131.00M
Float Shares:126.58M
Volume Ratio:2.83
T/O Rate:3.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3406
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-211.24%
PB:-10.41
PE(LYR):-1.63

Loading ...

Oncolytics Biotech Details on Intellectual Property Strategy

MT Newswires Live
·
Yesterday

Oncolytics provides intellectual property portfolio update

TIPRANKS
·
Yesterday

Oncolytics Biotech Says New Pelareorep Cancer Immunotherapy Method-of-Use Patent Issues in Several Countries

Reuters
·
Yesterday

Oncolytics Biotech® Secures Patent Protection to Late 2040S and Provides Intellectual Property Portfolio Update

THOMSON REUTERS
·
Yesterday

Oncolytics Biotech - Company Expects to Add New Composition of Matter Patent for Next Generation Pelareorep

THOMSON REUTERS
·
Yesterday

Oncolytics Biotech - New Method of Use Patent for Pelareorep Issued in Several Countries; U.S. Issuance Expected Soon

THOMSON REUTERS
·
Yesterday

Oncolytics Biotech - Three Patent Applications Pending; One to be Converted to Track One This Quarter

THOMSON REUTERS
·
Yesterday

Oncolytics announces publication of data on pelareorep in liver cancer

TIPRANKS
·
Sep 29

Oncolytics Biotech Says Study Shows Pelareorep Triggers Immune Activation in Liver Cancer, Boosting Immunotherapy Sensitivity

Reuters
·
Sep 29

Oncolytics reports accelerating enrollment in REO 033 study

TIPRANKS
·
Sep 28

Oncolytics Biotech - Expects Interim Part a Clinical Update by Year-End 2026

THOMSON REUTERS
·
Sep 28

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized Reo 033 Ras-Mutant, Mss Colorectal Cancer Study

THOMSON REUTERS
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Sep 28

Oncolytics Biotech (ONCY) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Oncolytics Reports Positive Preclinical Data Combining Pelareorep with Pan-RAS Inhibitor in Colorectal Cancer Model

Reuters
·
Sep 10

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-Ras Inhibitor in Colorectal Cancer

THOMSON REUTERS
·
Sep 10

Oncolytics Biotech Inc. : H.c. Wainwright Cuts Target Price to $5 from $10

THOMSON REUTERS
·
Aug 19

U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot

Reuters
·
Aug 19

Oncolytics aligns with FDA on path for REO 033 expansion study

TIPRANKS
·
Aug 18

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line Ras-Mutant Mss Colorectal Cancer

THOMSON REUTERS
·
Aug 18